Efficient synthesis of AMP579, a novel adenosine A1/A2 receptor agonist

[18F]fluoropyridines: From conventional radiotracers to the labeling of macromolecules such as proteins and oligonucleotides

Molecular in vivo imaging with the high-resolution and sensitive positron emission tomography (PET) technique requires the preparation of a positron-emitting radiolabeled probe or radiotracer. For this purpose, fluorine-18 is becoming increasingly the radionuclide of choice due to its adequate physical and nuclear characteristics, and also because of the successful use in clinical oncology of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), which is currently the most widely used PET-radiopharmaceutical and probably the driving force behind the growing availability and interest for this positron-emitter in radiopharmaceutical chemistry. With a few exceptions, radiofluorinations involving fluorine-18 of high specific radioactivity (e.g. > 185 GBq/micromole) had, until recently, been limited to nucleophilic substitutions in homoaromatic and aliphatic series with [18F]fluoride. Considering chemical structures showing a fluoropyridinyl moiety, nucleophilic heteroaromatic substitution at the ortho-position with no-carrier-added [l8F]fluoride, as its K[18F]F-K222 complex, appears today as a highly efficient method for the radiosynthesis of radiotracers and radiopharmaceuticals. This chapter summarizes the recent applications of this methodology and highlights its potential in the design and preparation of, often drug-based, fluorine-18-labeled probes of high specific radioactivity for PET imaging, including macromolecules of biological interest such as peptides, proteins and oligonucleotides.

Effects of AMP579 and adenosine on L-type Ca2+ current in isolated rat ventricular myocytes

AIM

To compare the effects of AMP579 and adenosine on L-type Ca2+ current (I(Ca-L)) in rat ventricular myocytes and explore the mechanism by which AMP579 acts on I(Ca-L).

METHODS

I(Ca-L) was recorded by patch-clamp technique in whole-cell configuration.

RESULTS

Adenosine (10 nmol/L to 50 micromol/L) showed no effect on basal I(Ca-L), but it inhibited the I(Ca-L) induced by isoproterenol 10 nmol/L in a concentration-dependent manner with the IC(50) of 13.06 micromol/L. Similar to adenosine, AMP579 also showed an inhibitory effect on the I(Ca-L) induced by isoproterenol. AMP579 and adenosine (both in 10 micromol/L) suppressed isoproterenol-induced ICa-L by 11.1% and 5.2%, respectively. In addition, AMP579 had a direct inhibitory effect on basal I(Ca-L) in a concentration-dependent manner with IC50 (1.17 micromol/L). PD116948 (30 micromol/L), an adenosine A1 receptor blocker, showed no action on the inhibitory effect of AMP579 on basal I(Ca-L). However, GF109203X (0.4 micromol/L), a special protein kinase C (PKC) blocker, could abolish the inhibitory effect of AMP579 on basal I(Ca-L). So the inhibitory effect of AMP579 on basal I(Ca-L) was induced through activating PKC, but not linked to adenosine A1 receptor.

CONCLUSION

AMP579 shows a stronger inhibitory effect than adenosine on the I(Ca-L) induced by isoproterenol. AMP579 also has a strong inhibitory effect on basal I(Ca-L) in rat ventricular myocytes. Activation of PKC is involved in the inhibitory effect of AMP579 on basal I(Ca-L) at downstream-mechanism.